Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The tissue factor pathway in ischemic stroke.

Murray J Adams1, Jim Thom, Graeme J Hankey

  • 1Western Australian Biomedical Research Institute, School of Biomedical Sciences, Curtin University, Perth, Australia.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|September 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot Randomized Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Newly Diagnosed Advanced Pancreatic Cancer (CanPan).

JCO oncology practice·2026
Same author

A Randomized, Open-Label Trial to Assess Feasibility and Tolerability of Topical Cannabis Balms for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS).

Cannabis and cannabinoid research·2025
Same author

Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study.

Research and practice in thrombosis and haemostasis·2023
Same author

Adenosine 2A Receptor Activation Amplifies Ibrutinib Antiplatelet Effect; Implications in Chronic Lymphocytic Leukemia.

Cancers·2022
Same author

Cannabis as an Anticancer Agent: A Review of Clinical Data and Assessment of Case Reports.

Cannabis and cannabinoid research·2021
Same author

A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2021
Same journal

Pampiniform venous plexus thrombosis in a 37 years-old male patient with severe thrombocytosis: a multifactorial aetiology.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

PROS1 Cys475Tyr mutation associated with a type III protein S deficiency pattern.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Genetic characterization of Glanzmann thrombasthenia: insights from novel igta2b mutations in a Tunisian patient cohort.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Uterine fibroids as an underrecognized risk factor for venous thromboembolism: a narrative review.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

SEER sonorheometry enhances fibrinolysis detection during liver transplantation with heparin.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
See all related articles

Blood markers of the tissue factor (TF) pathway show significant alterations in acute ischemic stroke. These changes, including increased TF pathway inhibitor activity (TFPIac) and decreased factor VIIa (FVIIa), may indicate altered clotting dynamics.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Neurology

Background:

  • The tissue factor (TF) pathway plays a critical role in hemostasis and thrombosis.
  • Dysregulation of the TF pathway is implicated in various thrombotic disorders, including ischemic stroke.
  • Understanding TF pathway marker dynamics in ischemic stroke is crucial for elucidating disease mechanisms.

Purpose of the Study:

  • To investigate the role of the TF pathway in ischemic stroke by measuring blood concentrations of key markers.
  • To compare TF pathway marker levels between ischemic stroke patients and healthy controls during acute and convalescent phases.
  • To determine the association between TF pathway markers and stroke risk.

Main Methods:

  • Blood concentrations of TF antigen, free TF pathway inhibitor antigen (TFPIf), TF pathway inhibitor activity (TFPIac), and activated factor VII (FVIIa) were measured.

Related Experiment Videos

  • Measurements were taken in 150 first-ever ischemic stroke patients and 150 community controls during the acute phase (within 7 days) and convalescent phase (3-6 months).
  • Statistical analyses were performed to compare marker levels and assess associations with stroke odds.

    • Main Results:

    • During the acute phase, TFPIac was increased and FVIIa was decreased in stroke patients compared to controls.
    • Increasing TFPIf and decreasing FVIIa and TFPIac were independently associated with stroke odds.
    • In the convalescent phase, TF antigen and TFPIf were significantly decreased in stroke patients.

    Conclusions:

    • Alterations in TF pathway marker concentrations are common in acute ischemic stroke.
    • Acute phase changes may involve enhanced TF-FVIIa complex formation and TFPI upregulation.
    • Chronic phase changes suggest ongoing consumption of TF antigen and TFPIf during plaque healing.